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ABSTRACT	
Rationale	We	 report	 the	 safety,	 biodistribution	 and	 internal	 radiation	 dosimetry,	 in	humans	with	 thyroid	 cancer,	 of	 18F-tetrafluoroborate	 (18F-TFB),	 a	 novel	 PET	radioligand	for	imaging	the	human	sodium/iodide	symporter	(hNIS).		
Methods	Serial	whole-body	PET	scans	of	5	subjects	with	recently	diagnosed	with	thyroid	cancer	were	acquired	prior	to	surgery	for	up	to	4	hours	after	injection	of	184	±	15	MBq	of	18F-TFB.	Activity	was	determined	in	whole	blood,	plasma	and	urine.	Mean	organ	absorbed	doses	and	effective	doses	were	calculated	via	quantitative	image	analysis	and	using	OLINDA/EXM	software.		
Results	Images	showed	high	uptake	of	18F-TFB	in	known	areas	of	high	hNIS	expression	(thyroid,	 salivary	glands	and	stomach).	Excretion	was	predominantly	 renal.	No	adverse	effects	 in	 relation	 to	 safety	of	 the	 radiopharmaceutical	were	observed.	The	 effective	 dose	was	 0.0326	 ±	 0.0018	mSv/MBq.	 The	 critical	 tissues/organs	receiving	the	highest	mean	sex-averaged	absorbed	doses	were	thyroid	(0.135	±	0.079	 mSv/MBq),	 stomach	 (0.069	 ±	 0.022	 mSv/MBq)	 and	 salivary	 glands	(parotids	 0.031	 ±	 0.011	 mSv/MBq,	 submandibular	 0.061	 ±	 0.031	 mSv/MBq).	Other	organs	of	interest	were	the	bladder	(0.102	±	0.046	mSv/MBq)	and	kidneys	(0.029	±	0.009	mSv/MBq).		
Conclusion	Imaging	 using	 18F-TFB	 imparts	 a	 radiation	 exposure	 similar	 in	 magnitude	 to	many	other	18F--labeled	radiotracers.	18F-TFB	shows	a	similar	biodistribution	to	 99mTc-pertechnetate,	 a	 known	 non-organified	 hNIS	 tracer,	 and	 is	
pharmacologically	and	radiobiologically	safe	in	humans.	Phase	2	trials	as	a	hNIS	imaging	agent	are	warranted.			
INTRODUCTION	
	 The	 human	 Na+/I-	 symporter	 hNIS	 is	 a	 plasma	membrane	 glycoprotein	that	mediates	active	I-	transport	into	thyroid	epithelial	and	follicular	cells.	It	also	mediates	 transport	 of	 I-	 into	 cells	 of	 other	 tissues	 that	 do	 not	 organify	 iodide,	such	 as	 the	 salivary	 glands,	 gastric	 mucosa	 and	 breast	 (1).	 As	 a	 target	 for	molecular	 imaging,	 its	 main	 clinical	 role	 has	 been	 in	 investigation	 of	 thyroid	pathophysiology.	 Radioiodine	 has	 historically	 been	 used	 for	 both	 diagnostic	thyroid	 imaging	 (using	 	 123I-I-)	 and	 to	 treat	 benign	 and	 malignant	 thyroid	disease	(using	131I-I-)	(2).	Due	to	its	similarity	of	volume	and	charge	with	iodide	ions,	 99mTc-NaTcO4-	 (sodium	 pertechnetate)	 is	 also	 widely	 used	 to	 study	thyroid	 function.	 To	 overcome	 the	 limitations	 of	 gamma	 camera	 planar	 and	single	 photon	 emission	 tomography	 imaging	 with	 respect	 to	 resolution	 and	senstivity,	 recent	 interest	 has	 focused	 on	 developing	 positron	 emission	tomography	(PET)	tracers	for	thyroid	imaging.			 Phan	et	al.	reported	that	124I-I-	PET	was	a	more	sensitive	diagnostic	tool	than	131I-I-	 scintigraphy	 in	20	patients	(3).	A	study	by	Gulec	et	al.	with	124I-I-	PET	identified	22.5%	more	iodine-avid	foci	than	with	planar	131I-I-	scintigraphy	post-treatment	 (4).	However,	 the	 complex	decay	 scheme	of	 iodine-124	 (5)	 and	low	 positron	 abundance	 result	 in	 poor	 PET	 imaging	 characteristics.	 Optimal	target:	 background	 ratios	 are	 reported	 after	 24	 hours.	 It	 requires	 a	 complex	cyclotron-based	production	and	purification	process	(6)	and	due	to	its	relatively	
long	half-life	of	4.2	days	 lead	to	a	high	effective	dose	(0.095-1.5	mSv/MBq)	(7).	Because	of	 the	superior	PET-imaging	characteristics	and	dosimetry	of	 fluorine-18,	a	reliable	and	sensitive	18F-based	radioligand	for	hNIS	would	have	potential	for	molecular	 imaging	of	hNIS	activity.	Several	small	anionic	species	containing	fluorine,	 such	 as	 tetrafluoroborate	 (BF4-),	 fluorosulfate	 (SO3F-),	hexafluorophosphate	(PF6-)	and	difluorophosphate	(PO2F2-)	have	been	identified	as	hNIS	substrates	(8,	9).	While	18F-SO3F-	was	only	recently	synthesized	for	the	first	time	and	shown	to	be	an	effective	high-affinity	NIS	tracer	in	mice	(10),	 the	earliest	 reports	 of	 18F-BF4-	 date	 from	 the	 1960’s	 (11-13).	 Our	 group	 recently	developed	 a	 method	 for	 the	 synthesis	 of	 18F-tetrafluoroborate	 (18F-TFB)	suitable	 for	 routine	 clinical	 production,	 and	 showed	 it	 to	 be	 a	 tracer	 for	 hNIS,	with	 similar	 biological	 behavior	 to	 99mTc-TcO4-	 in	 vitro	 and	 in	 mice	 (14-16).	Marti-Climent	et	al.	detailed	the	characteristic	biodistribution	of	18F-TFB	in	NIS	expressing	tissues	in	cynomolgus	primates,	with	uptake	in	the	thyroid,	stomach	and	salivary	glands,	and	a	mean	whole	body	absorbed	dose	of	0.0247	mSv/MBq	
(17).	Given	the	potential	of	an	18F-based	radioligand	for	diagnosis	and	treatment	planning	 in	 thyroid	 disease,	 we	 investigated	 the	 safety,	 biodistribution	 and	radiation	dosimetry	18F-TFB	in	a	human	population.			
	
MATERIALS	&	METHODS	
	
Radiopharmaceutical	Preparation		 Synthesis	 of	 the	 18F-TFB	 IMP	 (Investigational	 Medicinal	 Product)	 was	carried	 out	 by	 a	method	 similar	 to	 a	 previously	 described	 automated	 labeling	protocol	 (14)	using	an	Eckert	and	Ziegler	Modular-Lab	synthesis	unit	 (Imaging	
Equipment	Ltd.,	Bristol,	UK).	18F-fluoride	 (46	±	6	GBq),	obtained	 from	proton-irradiated	[18O]water	(98	atom%,	Rotem	Industries	Ltd.,	Israel;	11	MeV	protons	from	a	CTI	RDS	112	cyclotron,	beam	current	30	μA,	irradiation	time	60	min),	was	trapped	in	a	QMA	cartridge	(Sep-Pak	Light	QMA	cartridge,	Waters,	Elstree,	UK)	conditioned	 with	 1.0	M	 sodium	 hydrogen	 carbonate	 (10	 mL,	 Ph	 Eur,	Merck)	followed	 by	 water	 for	 injections	 (10	 mL,	 BP,	 Hamelin	 Pharmaceuticals,	Gloucester,	UK)	and	air	(10	mL).	Hydrochloric	acid	(1.5	M,	1.2	mL),	prepared	by	dilution	 of	 hydrochloric	 acid	 fuming	 37%	 (Ph	 Eur,	 Merck)	 with	 water	 for	injections	 (BP,	 Hameln	 Pharmaceuticals,	 Gloucester,	 UK),	 was	 then	 passed	through	 the	 QMA	 cartridge,	 eluting	 the	 18F-fluoride	 into	 the	 reactor	 which	contained	 sodium	 tetrafluoroborate	 (Sigma-Aldrich,	 Gillingham,	 UK)	 (1	mg	 in	0.1	mL	water	for	injections).	The	reaction	mixture	(1.3	mL)	was	heated	to	80	°C	for	 15	min,	 cooled	 to	 20	 °C	 and	 passed	 through	 a	 silver	 ion-loaded	 cation	exchange	cartridge	(OnGuard	 II	AG,	Dionex,	Leeds,	UK,	conditioned	with	10	mL	water	and	5	mL	air)	to	remove	chloride	ions	and	raise	the	pH,	and	through	two	alumina	 cartridges	 (Waters	 SepPak	 Light	 Alumina	 N,	 conditioned	 with	 10	mL	water	and	5	mL	air)	to	remove	unreacted	18F-fluoride.	The	product	was	eluted	with	water	for	injections	(2	mL)	into	a	nitrogen-filled	USP	type	1	glass	sterile	vial	(N46,	 GE	 Healthcare)	 containing	 water	 for	 injections	 (2	 mL).	 Following	production,	 the	vial	containing	the	unfiltered	product	(5.3	mL)	was	transferred	to	 a	 sterile	 isolator,	 for	 sterile	 filtration	 and	 quality	 control	 sampling.	 The	process	 was	 validated	 to	 demonstrate	 that	 18F-TFB	 can	 be	 consistently	manufactured	 on	 the	 Modular-Lab	 synthesizer	 to	 meet	 the	 required	 quality	control	 release	 specifications.	 Stability	 studies	 were	 conducted	 by	 testing	 an	aliquot	from	the	validation	batches	for	radiochemical	purity	and	pH	at	2,	4	and	6	
hours	from	end	of	synthesis.		
	
Radiopharmaceutical	quality	control		 Radiochemical	 identity,	 purity	 and	 specific	 activity	 of	 the	 final	 product	were	checked	by	 ion	chromatography	(Metrohm	930	Compact	IC	Flex)	with	 in-line	conductimetric	and	gamma	detectors	(B-FC-3200,	LabLogic)	using	a	Shodex	IC	I-524A	column	(4.6 × 100	mm)	with	2.5	mM	phthalic	acid	(adjusted	to	pH	4.0	with	 tris(hydroxymethyl)aminomethane)	 as	 eluent.	 The	 flow	 rate	 was	1.5	mL/min,	and	column	temperature	was	40	°C.	The	IC	quality	control	method	was	 validated	 following	 the	 International	 Conference	 on	 Harmonisation	guidelines	 and	 the	 concentration	 of	 [19/18F-]	 BF4-	 in	 the	 final	 product	 was	determined	 from	 the	 ion	 chromatogram	 by	 reference	 to	 a	 calibration	 curve.	RadioTLC	was	carried	out	using	a	 silica	gel	 stationary	phase	 (Silica	gel	60	F254,	5 × 10	cm,	Merck)	with	methanol	as	the	mobile	phase.	Plates	were	scanned	using	a	 radio-TLC	scanner	(LabLogic	Scan-RAM	)	 with	 a	 β+	 probe	 (PS	 Plastic-PM	LabLogic).	 The	 radiochemical	 purity	 of	 the	 product	 was	 determined	 as	 the	radioactivity	 associated	with	 the	 tetrafluoroborate	 peak	 (Rf	 = 0.6,	 c.f.	Rf = 0	 for	fluoride)	as	a	percentage	of	the	total	chromatogram	radioactivity.	Silver	content	was	 determined	 using	 Quantofix	 Silver	 test	 strips	 (Macherey-Nagel).	 The	bacterial	 endotoxin	 assay	 was	 performed	 using	 the	 Endosafe	 Portable	 Test	System	(Charles-River)	using	LAL	reagent	water	and	licensed	Endosafe	Portable	Test	System	cartridges	(Charles	River)	with	sensitivity	of	0.05	-	5.0	EU/mL.	The	integrity	 of	 the	 sterilizing	 filters	 was	 tested	 after	 use	 using	 the	 bubble	 point	method	and	sterility	testing	was	carried	out	by	Wickham	Laboratories.	
	
	
Patients		Patients	were	recruited	in	accordance	with	the	European	Council	Directive.	The		clinical	 protocol	 was	 approved	 by	 the	 local	 Research	 Ethics	 Committee	(reference	 number	 14/LO/1247,	 ISRCTN:	 75827286).	 All	patients	 provided	written	informed	consent. Five	 subjects	 (2	 male,	 3	 female,	 average	 age	 46	 years)	 with	 newly	diagnosed,	cytologically	confirmed	thyroid	cancer	were	imaged	prior	to	elective	total	 thyroidectomy	 and	 131I-NaI	 thyroid	 remnant	 ablation.	 Pregnant	 and	lactating	women	were	excluded.			 A	cannula	was	placed	 in	a	vein	 in	the	antecubital	 fossa	of	each	arm,	one	for	injection	of	18F-TFB	and	the	other	for	withdrawal	of	venous	blood.	Electro-cardiographic	 monitoring,	 pulse,	 blood	 pressure,	 body	 temperature	 (using	 a	temperature	 strip	 on	 the	 patient’s	 forehead)	 and	 respiratory	 rate	 were	monitored	throughout	the	study.			
PET-CT	data	acquisition		 Bolus	injection	of	18F-TFB	(mean	185	±	15	MBq)	was	performed	with	the	patient	positioned	on	the	scanning	couch.	Imaging	comprised	a	90-minute	series	of	 7	 sequential	 whole	 body	 PET–CT	 scans	 (from	 head	 to	 foot),	 followed	 by	 2	further	 whole	 body	 PET-CT	 scans	 at	 120	 and	 240	minutes	 post-injection	 (see	Figure	1)	with	a	GE	Discovery	710	PET-CT	scanner	 (GE	Healthcare,	Waukesha,	USA)	with	an	axial	field	of	view	of	15.7	cm.	Each	scan	covered	the	vertex	to	mid-thigh,	 with	 an	 11-slice	 overlap	 between	 bed	 positions.	 Three	 low-dose	 whole	body	 CT	 scans	 (140	 kV,	 10	mA,	 0.5	 s	 rotation	 time,	 40	mm	 collimation)	were	
performed,	 one	 prior	 to	 the	 block	 of	 7	 sequential	 scans	 and	 then	 one	 prior	 to	each	 of	 the	 scans	 at	 120	 and	 240	 minutes,	 for	 attenuation	 correction	 and	anatomical	reference.	The	initial	1	minute	per	bed	scan	duration	was	adjusted	to	compensate	 for	 radioactive	decay	up	 to	 a	maximum	of	3	minutes/bed	 step	 for	the	final	scan	at	240	min.			
Quantification	of	blood	and	urine	data		 Venous	blood	samples	(5	mL	each)	were	acquired	at	0,	1,	2,	5,	10,	20,	40,	60,	 90,	 120	 and	 240	minutes	 post	 injection.	 Three	 0.2	mL	 aliquots	 from	 each	blood	 sample	 were	 weighed	 and	 counted	 on	 a	 10-sample	 well	 counter	 (2470	WIZARD2,	PerkinElmer,	London,	UK),	previously	cross-calibrated	with	fluorine-18	 to	 the	 PET	 scanner	 using	 a	 standard	 calibration	 technique	 subject	 to	 daily	quality	 control.	 Whole	 blood	 samples	 were	 centrifuged	 for	 5	 minutes	 (6000	rpm),	and	three	0.2	mL	samples	of	plasma	from	each	were	then	counted	in	the	well	 counter.	Following	 the	method	of	Namias	et	al.	 (18),	 the	distribution	ratio	
R(t),	 between	 blood	 cells	 and	 plasma	 can	 be	 calculated	 from	 experimental	measurements	of	 the	whole	blood	and	plasma	activity	concentrations	(CWB	and	
CP	respectively)	at	each	time	point	using	the	equation:	𝑅 𝑡 = 𝐶!" 𝑡 𝐶! (𝑡)																																																														[1]	where	the	blood	cell	activity	concentration,	CBC,	can	be	calculated	from:	𝐶!" 𝑡 = !!" ! ! !!! !! !!                                                             [2]	
The	value	H	represents	hematocrit	(assumed	for	each	patient	as	H=0.39).	Before	application	of	equations	[1]	and	[2],	CBC	and	CP	were	expressed	in	Bq/kg	of	water,	
assuming	 that	 plasma	 contains	 0.94	 kg	water/L	 and	 erythrocytes	 contain	 0.73	kg/L	(19).		
Urine	 was	 collected	 as	 voided	 in	 the	 intervals	 between	 imaging	 (i.e.	between	 90-120	 minutes	 and	 140-260	 minutes),	 weighed	 for	 total	 excreted	volume,	and	 three	aliquots	 (0.2	mL	each)	of	each	void	were	used	 to	determine	the	total	excreted	activity	of	18F-TFB.			
Image	Reconstruction	
	 Each	 whole	 body	 PET	 image	 was	 attenuation-corrected	 using	 its	corresponding	 CT	 image	 and	 included	 standard	 scanner-based	 corrections	 for	decay,	 scatter,	 randoms	 and	 dead-time.	 Each	 emission	 scan	was	 reconstructed	with	a	 time-of-flight	OSEM	algorithm	(2	 iterations,	24	subsets),	 into	a	256x256	matrix.	 	 A	 4	 mm	 full	 width	 at	 half	 maximum	 Gaussian	 post-reconstruction	smoothing	 filter	 was	 applied.	 Accuracy	 of	 the	 activity	 in	 the	 PET	 images	 was	verified	by	summing	the	activity	in	the	first	whole-body	PET	scan	and	comparing	with	the	decayed	injected	activity.	
	
Absorbed	dose	calculations	
	 Whole	 body	 CT	 images	 from	 the	 120	 and	 240	min	 PET-CT	 scans	 were	rigidly	 registered	 to	 the	 0-90	 min	 CT	 using	 the	 PFUS	 package	 of	 PMOD	 v3.7	(PMOD	Technologies,	 Zurich,	 Switzerland).	The	 resulting	 transformations	were	then	applied	to	the	corresponding	PET	images.	All	PET	frames	were	then	merged	to	a	single	4D	series	decay-corrected	to	a	common	time	point.	Organs	of	interest	were	 identified	 and	 manually	 delineated	 by	 an	 experienced	 clinician	 using	 a	fusion	of	both	the	corresponding	CT	and	PET	images.	A	software	correction	was	
included	to	account	for	the	imaging	time	of	each	bed	position	in	the	WB	sweeps.	Visible	 organs	 with	 high	 uptake	 or	 easily	 identified	 on	 CT	 imaging	 were	 the	brain,	 thyroid,	 liver,	 spleen,	 stomach,	 heart,	 kidneys,	 lungs,	 testes	 (male	 only)	and	urinary	bladder	contents.	Organ	volumes	were	transferred	to	all	frames	and	independent	 volumes	 were	 adjusted	 where	 necessary	 to	 account	 for	 any	movement	of	organs	between	different	frames.	All	organs	with	the	exception	of	the	bladder	were	assumed	to	have	a	constant	volume	over	time.	The	volume	of	the	 bladder	 was	 quantified	 on	 each	 PET	 scan	 using	 a	 25%	 of	 maximum	isocontour.	 PMOD	 software	 allows	 the	 automatic	 naming	 and	 standardized	volume	determination	of	each	organ	relating	to	the	70	kg	Cristy-Eckerman	adult	anthropomorphic	 phantom	 employed	 by	 OLINDA/EXM	 (Organ	 Level	 Internal	Dose	Assessment/Exponential	Modeling)	 dose	 calculation	 software,	 a	 software	package	widely	used	to	obtain	radiation	dose	estimates	 in	radiopharmaceutical	studies	 (20).	 Time-activity	 curves	 (TACs)	 were	 produced	 for	 each	 organ,	 and	using	 the	PKIN	package	of	PMOD	v3.7.	Organ	 ‘normalized	cumulated	activities’	(NCA	 –	 numerically	 equivalent	 to	 the	 older	 terminology	 of	 ‘residence	 time’	measured	 in	MBq.h/MBq)	were	 automatically	 calculated	using	 the	net	 injected	activity	 and	organ	volume.	TACs	were	 fitted	 to	bi-exponential	 functions	where	possible,	assuming	radionuclide	decay	(i.e.	no	 further	excretion)	upon	reaching	the	 last	 imaging	 point.	 Mean	 blood	 activity	 concentration	 was	 generated	 in	calibrated	 kBq/mL	 from	 the	 average	 value	 of	 the	 three	 samples.	 Total	 blood	activity	was	calculated	assuming	5.4%	of	the	reference	phantom’s	mass	(70	kg)	was	 blood.	 The	 blood	 TAC	 was	 fitted	 with	 an	 exponential	 curve,	 the	 NCA	determined	 and	 this	 value	 used	 as	 the	 NCA	 for	 the	 red	 marrow	 in	 OLINDA	calculations.		
Summed activities of the urinary bladder and voided urine over the course of 
the study were fitted with a 1-phase exponential curve using the formula: 
𝑈 𝑡 = 𝑈!"#× 1 − exp − ln 2× !!!!                                    [3]	
 
 where	 U(t),	 Umax	 and	 T1/2	 represent	 the	 accumulated	 urine	 activity	 at	 time	 t,	maximum	accumulated	urine	activity	and	biological	half-life	 respectively.	From	the	 fitting	 parameters,	 Umax	 and	 T1/2	 were	 determined	 and	 the NCA of the 
urinary bladder contents was calculated using a dynamic urinary bladder model 
in the OLINDA/EXM v1.1 software.	 A	 3.5	 hour	 voiding	 interval	was	 used	 as	recommended	 by	 the	 ICRP	 (21).	 The	 “remainder	 of	 body”	 was	 assigned	 by	activity	 not	 accounted	 for	 by	 organ	 delineation	 or	 excretion.	 Effective	 doses	according	 to	 the	 tissue	weighting	 factors	 of	 ICRP	Publication	60	 in	 each	 organ	were	calculated	by	inputting	calculated	NCAs	into	OLINDA/EXM.	Absorbed	doses	to	the	24	organs	specified	by	the	Medical	Internal	Radiation	Dose	scheme	in	the	target	 organs	 of	 the	 Cristy-Eckerman	 adult	 hermaphrodite	 male	 and	 female	phantoms	 were	 determined,	 and	 sex-specific	 absorbed	 doses	 were	 averaged.	Gonad	 absorbed	 dose	was	 taken	 to	 be	 the	mean	 of	 the	 absorbed	 doses	 to	 the	testes	and	ovaries.	Absorbed	doses	to	the	salivary	glands,	which	are	not	assigned	organs	in	the	OLINDA/EXM	scheme,	were	also	investigated.	The	submandibular	and	parotid	glands	were	assigned	a	mass	of	9.9	g	and	18	g	 respectively	with	a	density	 of	 1	 cm3/g	 (values	 previously	 used	 for	 salivary	 gland	 dosimetric	purposes	 (22)).	 NCAs	 for	 each	 gland	 from	 imaging	 were	 inputted	 into	 the	“Spheres”	 module	 of	 the	 OLINDA/EXM	 software,	 and	 a	 curve	 of	 the	 form	
𝑑 = 𝑎×𝑚! was	fitted	to	the	resulting	dose	(mGy/MBq)	to	mass	(g)	relationship	to	determine	the	dose	at	the	mass	of	the	gland	under	investigation.						
RESULTS		
Safety	In	 all	 18F-TFB	batches,	 radiochemical	 purity	was	 >	 99.8%	 as	 shown	 by	radio-IC	and	 radio-TLC,	no	 silver	was	detected,	 radionuclidic	purity	was	100%	and	 no	 impurities	were	 found.	 All	 batches	were	 sterile	 and	 pyrogen	 free.	 The	mean	and	standard	deviation	of	the	administered	mass	of	19F/18F-TFB	was	9	±	4	μg	and	the	specific	activity	at	the	time	of	injection	was	24	±	13	MBq/μg.	18F-TFB	 was	 found	 to	 be	 safe	 and	 well-tolerated	 by	 all	 patients.	 There	 were	 no	adverse	or	clinically	detectable	pharmacologic	effects	in	any	of	the	5	subjects.	No	significant	changes	in	vital	signs	or	electro-	cardiograms	were	observed.		
		
Biodistribution	Figure	 2	 shows	 the	 biodistribution	 of	 18F-TFB	 over	 time	 for	 a	 single	representative	 patient.	 All	 patients	 showed	 similar	 biodistribution	characteristics.	 The	 thyroid	 is	 clearly	 visible	 from	 the	 earliest	 time	point,	with	uptake	 reaching	 a	 peak	 at	 approximately	 30	 minutes	 post-injection	 for	 all	patients.	 Outside	 the	 thyroid,	 reconstructed	 images	 show	high	 uptake	 in	 other	areas	 of	 elevated	 hNIS	 expression,	 such	 as	 the	 salivary	 glands	 and	 stomach.	Excretion	was	primarily	renal.	Esophageal	transit	of	18F-TFB	can	be	observed	at	later	 time	 points	 as	 saliva	 generated	 in	 the	 salivary	 glands	 is	 swallowed	 and	enters	 the	stomach	and	 intestinal	system.	The	oral	cavity	also	shows	 increased	
activity	1	hour	post-injection,	probably	due	to	pooling	of	saliva.	Images	show	low	uptake	in	areas	that	do	not	significantly	express	hNIS,	such	as	the	brain	and	liver.		Tumour	nodules	ranging	in	size	from	13	–	114mm	maximum	diameter	are	photopaenic	against	background	healthy	thyroid	18F-TFB	uptake,	consistent	with	lower	hNIS	expression	in	DTC	relative	to	normal	thyroid.		Persisting	low	intensity	blood	pool	activity	was	observed	on	delayed	images.		
	 Figure	3	shows	 the	average	percent	of	 injected	activity	over	all	patients	for	a	range	of	organs	considered	for	dosimetric	purposes	while	Figure	4	details	the	plasma	and	blood	activity	concentrations	as	well	as	the	distribution	ratio	of	the	radiotracer.			
Radiation	Dosimetry	
	 Using	TACs	derived	from	biodistribution	imaging,	the	absorbed	doses	per	unit	administered	activity	to	the	Medical	 Internal	Radiation	Dose	scheme	listed	organs,	as	determined	from	OLINDA	and	averaged	over	all	patients,	are	provided	in	Table	1.	The	highest	absorbed	organ	doses	were	those	to	the	thyroid,	stomach	and	bladder.		
 
DISCUSSION 
 This	 work	 presents	 the	 first	 study	 of	 the	 biodistribution	 and	 radiation	dosimetry	of	18F-TFB	in	humans.	Previous	work	in	primates	(also	using	OLINDA	and	 assuming	 distribution	 in	 the	 Cristy-Eckerman	 phantom)	 demonstrated	 a	whole	 body	 absorbed	 effective	 dose	 of	 0.0247	 ±	 0.0028	 mSv/MBq,	 which	compares	well	with	our	calculated	value	of	0.0326	±	0.0018	mSv/MBq	averaged	
over	 men	 and	 women,	 despite	 physiological	 differences	 between	 humans	 and	primates.	As	evident	 in	Figure	2,	organs	with	highest	 tracer	uptake	correspond	to	tissues	associated	with	high	hNIS	expression.	Increased	uptake	in	the	stomach	reflects	 a	 combination	 of	 hNIS	 expression	 and	 swallowed	 saliva,	 following	secretion	 by	 the	 salivary	 glands.	 Images	 are	 consistent	 with	 18F-TFB	 passing	from	 the	 salivary	 glands	 into	 the	 mouth	 and	 through	 the	 esophagus	 into	 the	stomach.	The	average	mass	of	 tetrafluoroborate	 injected	(9	µg)	corresponds	 to	approximately	 0.1	 µmol,	 which	 assuming	 a	 total	 extracellular	 fluid	 volume	(including	 plasma)	 of	 15	 L	 would	 lead	 to	 a	 maximum	 concentration	 of	tetrafluoroborate	 in	 extracellular	 fluid	 of	 around	 7	 nM,	 much	 lower	 than	 the	range	 of	 values	 reported	 for	 the	 IC50	 of	 tetrafluoroborate	 (ca.	 1	 µM)	 (10).	Therefore	 it	 is	unlikely	 that	significant	blocking	of	hNIS	occurs	 in	 these	studies	despite	reported	concerns	(15).			 The	 large	 standard	 deviations	 observed	 in	 the	 organs	 and	 tissues	 with	high	hNIS	expression,	such	as	the	thyroid	and	salivary	glands,	show	that	uptake	in	these	tissues	is	variable	amongst	the	small	population	studied.	As	detailed	in	Figure	 4,	 blood	 and	 plasma	 sample	 counting	 shows	 that	 18F-TFB	 equilibrates	between	 plasma	 and	 blood	 cells,	 with	 the	 distribution	 ratio	 converging	 to	 a	constant	value	of	approximately	0.74	by	30	minutes.	 		 Matched	 radionuclide	 pairs	 for	 diagnostic	 imaging	 and	 radionuclide	treatment	are	an	integral	part	of	nuclear	medicine	and	the	field	has	attracted	the	name	 “theranostics”.	 99mTc-TcO4-	 is	 often	 used	 to	 estimate	 accumulation	 and	trapping	function	prior	to	131I-I	treatment	of	hyperthyroidism	(23),	the	pattern	and	intensity	of	99mTc-TcO4-	uptake	indicating	the	aetiology	of	hyperthyroidism	(Grave’s	 disease,	 multinodular	 goiter,	 thyroiditis).	 Comparisons	 have	 shown	
good	imaging	concordance	between	radioiodine	and	99mTc-TcO4-	(24,	25).	Like	99mTc-TcO4-,	 18F-TFB	 is	 trapped	 but	 not	 organified	 by	 the	 thyroid.	 Further	investigation	of	its	potential	as	a	diagnostic	in	hyperthyroidism	and	comparison	with	 99mTc-TcO4-	 are	 warranted.	 18F-TFB	 may	 have	 applications	 for	 TSH	stimulated	 detection	 of	 differentiated	 thyroid	 cancer	 metastases	 following	surgery	and	thyroid	remnant	ablation	as	an	imaging	partner	for	131I-I-	therapy.	By	 comparison	 with	 I-124	 I-PET,	 18F-TFB	 offers	 a	 low	 absorbed	 dose	 and	favorable	imaging	characteristics	that	allow	early	imaging	by	comparison	with	I-124	I-	PET.		18F-TFB	may	also	have	potential	for	the	investigation	of	other	hNIS	expressing	tumour	types	such	as	breast	and	salivary	gland	cancers.		 There	 are	 limitations	with	 assuming	 organs	 and	 tissues	 as	 unit	 density	spheres	 as	 employed	 here	 for	 calculation	 of	 radiation	 doses	 to	 organs	 not	present	 in	 the	 OLINDA	 models,	 with	 some	 reports	 showing	 differences	 in	radiation	 dose	 of	 over	 100%	between	 this	method	 and	 “gold	 standard”	Monte	Carlo	simulations	(26).	These	differences	mainly	arise	due	to	differences	in	tissue	geometry	compared	to	a	true	sphere.	Although	the	unit	density	spheres	model	is	only	 an	 approximation	 to	 clinical	 reality,	 our	 results	 are	 on	 the	 same	order	 as	previous	 works	 in	 primates,	 which	 also	 used	 the	 same	 methodology	 for	calculation	 of	 the	 salivary	 gland	 doses	 (17)	 (literature	 values:	 parotid:0.0413	mGy/MBq;	submandibular	gland:	0.0274	mGy/MBq).			 In	comparison	to	other	commonly	used	radiotracers	employed	in	thyroid	imaging,	Table	2	shows	that	18F-TFB	delivers	a	much	lower	absorbed	radiation	dose	 than	 the	radioiodine	 family	of	 tracers	 for	both	medium	and	high	 levels	of	thyroid	 uptake.	 Image	 quality	 within	 1	 hour	 of	 administration	 (mean	
administered	 activity	 185	 MBq)	 was	 consistently	 excellent	 in	 this	 pilot	 study.	Future	studies	may	be	able	to	optimize	the	injected	activity.			
Conclusion	
18F-TFB	 is	 a	 hNIS	 substrate	 analogous	 in	 biodistribution	 to	 99mTc-pertechnetate	and	is	taken	up	selectively	in	hNIS-expressing	tissues.	It	is	safe	to	administer	 in	 humans	 and	 its	 biodistribution	 and	 dosimetry	 warrant	 further	clinical	evaluation	as	a	PET	tracer	for	imaging	thyroid	pathophysiology	and	hNIS	expression.	
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FIGURE	LEGENDS			
		
	FIGURE	1.	Imaging	scan	schedule	for	the	whole-body	dynamic	PET-CT	study	(not	to	scale).	Dots	above	the	scan	positions	show	the	timings	of	venous	blood	sampling	and	squares	represent	nominal	urine	sampling	times.									
	
	FIGURE	 2.	 Decay-corrected	 serial	 maximum-intensity	 projections	 showing	 the	biodistribution	 of	 18F-TFB	 over	 the	 course	 of	 the	 imaging	 study.	 Thyroid,	salivary	 gland	 and	 stomach	 activities	 increase	 rapidly	 with	 time	 up	 to	 30	minutes.	Image	captioned	t	=	0-9	min	represents	the	first	imaging	frame.			
	FIGURE	3.	Percentage	of	injected	dose	per	gram	of	tissue	(%ID/g)	curves	for	selected	organs,	averaged	over	all	5	patients.	Large	standard	deviations	are	evident	in	the	hNIS	expressing	tissues	and	organs 	
		FIGURE	4.	Top	-	Mean	decay-corrected	blood	and	plasma	curves	averaged	over	all	 5	patients.	Bottom	 -	mean	blood	 cells	 to	plasma	distribution	 ratio,	 showing	that	equilibrium	 is	 reached	after	approximately	30	minutes.	Error	bars	 in	both	plots	represent	1	standard	deviation	of	the	mean.											
	
	
TABLES		
Organ/Tissue	 Mean	(mSv/MBq)	 Std.	dev.	(mSv/MBq)	
Gonads	 0.020	 0.014	
Adrenals	 0.015	 0.003	
Brain	 0.005	 0.001	
Breasts	 0.009	 0.003	
Gallbladder	Wall	 0.015	 0.004	
LLI	Wall	 0.016	 0.004	
Small	Intestine	 0.014	 0.003	
Stomach	Wall	 0.069	 0.022	
ULI	Wall	 0.014	 0.004	
Heart	Wall	 0.018	 0.004	
Kidneys	 0.029	 0.009	
Liver	 0.018	 0.004	
Lungs	 0.011	 0.003	
Muscle	 0.011	 0.003	
Pancreas	 0.018	 0.004	
Marrow	 0.034	 0.003	
Osteogenic	Cells	 0.033	 0.005	
Skin	 0.008	 0.002	
Spleen	 0.020	 0.003	
Thymus	 0.011	 0.003	
Thyroid	 0.135	 0.079	
Urinary	Bladder	wall	 0.102	 0.046	
Uterus	 0.019	 0.004	
Total	Body	 0.011	 0.003	
		 		 		
*Parotid	 0.031	 0.011	
*Submandibular	 0.061	 0.031	
		
	
		
Effective	Dose	 0.0326	 0.0018		
	TABLE	1.	Radiation	absorbed	doses	for	organs	identified	in	the	Medical	Internal	Radiation	Dose	schema.	*	Denotes	organs	that	are	not	in	the	OLINDA	model,	with	absorbed	 dose	 (in	mGy/MBq)	 estimated	 from	 the	 “Spheres”	model	 within	 the	OLINDA/EXM	software.				
Radiopharmaceutical	 Effective	 dose	(mSv/MBq)	 Nominal	Imaging	Activity	(MBq)(27)	131I-I-	 22*,	29	†		 3-10	[123I]I-	 0.23	‡		0.31§	 20	[124I]I-	 13‡,	18§	 50	99mTc-TcO4-	 0.013║		 80	18F-TFB	 0.0289	 200	18F-FDG	 0.019	 400		*medium	thyroid	uptake,	no	blocking,	oral	admin,	adult	†	high	thyroid	uptake,	no	blocking,	oral	admin,	adult	‡medium	thyroid	uptake,	no	blocking,	IV	admin,	adult	§high	thyroid	uptake	no	blocking,	IV	admin,	adult	
║	IV	administration,	adult		TABLE	2.	Comparison	of	the	whole	body	effective	doses	in	mSv/MBq	for	a	range	of	radiotracers	utilized	for	imaging	of	the	thyroid.	All	values	except	18F-TFB	are	from	ICRP	Publication	128	(28).	FDG	value	from	(29).			
